SHERIDAN, WYOMING – May 11, 2025 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has announced unanimous shareholder approval of all proposals presented at its 2025 Annual General Meeting (AGM), reinforcing the company’s commitment to strong corporate governance, strategic continuity, and long-term value creation.
The AGM resolutions, which include key board appointments and financial authorizations, position Philips to maintain momentum in executing its innovation-driven strategy across global health systems. Among the most notable outcomes were the re-appointments of seasoned Supervisory Board members Ms. Indra Nooyi and Ms. Chua Sock Koong, as well as the appointment of Mr. Bob White, a well-respected health technology executive, to the Supervisory Board.
Strengthening Strategic Leadership
Philips emphasized continuity and deep expertise in its board leadership. The re-appointment of Mr. Marnix van Ginneken to the Board of Management further underscores the company’s focus on stability and international governance capabilities.
Feike Sijbesma, Chairman of the Supervisory Board, highlighted the value of the board's experience, stating, “We are also delighted to welcome Bob White to the Supervisory Board and are very pleased with the re-appointment of Indra Nooyi and Chua Sock Koong. With our highly knowledgeable and experienced members, our Supervisory Board is well-equipped to advise and support Management as they execute Philips’ strategy.”
Sijbesma also recognized the contribution of departing board member David Pyott, extending “heartfelt thanks for his invaluable counsel over the past decade.”
Operational Continuity and Governance Confidence
The AGM resolutions reaffirm Philips’ strategic focus through key board decisions, including:
- Re-appointment of Indra Nooyi and Chua Sock Koong to the Supervisory Board
- Appointment of Bob White as a new Supervisory Board member
- Re-appointment of Marnix van Ginneken to the Board of Management
- Full discharge of responsibilities for the 2024 fiscal year to the Supervisory Board and Board of Management
- Approval of a €0.85 dividend per common share, payable in shares or (under conditions) in cash
- Approval of 2024 financial statements and the Remuneration Report
Roy Jakobs, CEO of Royal Philips, reinforced the significance of the board structure, saying, “Bob White is a recognized global business leader with deep expertise in health technology. Philips has benefited greatly from the expertise and contributions of Indra Nooyi and Chua Sock Koong… We look forward to continued successful collaboration with Marnix van Ginneken who has been instrumental to Philips, as we strive to improve health and well-being of people through meaningful innovation.”
Enhanced Shareholder Value and Financial Stewardship
Philips shareholders also approved proposals enabling continued financial agility:
- Authorization for the Board of Management to issue shares and manage pre-emption rights
- Authorization to acquire company shares
- Cancellation of existing shares
These measures provide Philips with flexibility to manage its capital structure and pursue strategic opportunities in a dynamic global healthcare market.
Driving Sustainable Innovation in Health Technology
The outcomes of the AGM 2025 reflect Philips’ ongoing commitment to shareholder value, operational excellence, and governance transparency—critical pillars as the company advances its vision to improve 2.5 billion lives per year by 2030 through innovations in diagnostics, patient monitoring, and connected care.
With renewed leadership and clear mandates, Philips is strategically positioned to address global health system challenges, accelerate innovation, and deepen its impact across care delivery networks.
Learn more about Philips’ corporate governance and AGM results at www.philips.com.